Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02421978 · ClinicalTrials.gov registry record

Inflammation-Induced CNS Glutamate During Breast Cancer Treatment

A clinical trial of Breast Cancer, sponsored by Emory University.

Completed
Registry status
98
Enrollment target
1
Study location

NCT02421978: Completed study of Breast Cancer, sponsored by Emory University.

NCT02421978 is a study of Breast Cancer that has completed, run by Emory University. The registered enrollment target is 98 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02421978, a study of Breast Cancer, has completed, sponsored by Emory University.

COMPLETED
Registry status
98 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to try and provide data linking the impact of increased inflammatory cytokines as a result of chemotherapy and their relationship with increased levels of CNS glutamate and related behavioral and cognitive consequences in breast cancer patients. The investigators will use neuropsychiatric assessments, blood sampling and Magnetic Resonance Spectroscopy (MRS) to collect study data.

Primary Outcome

Single voxel MRS (Magnetic Resonance Spectroscopy) scans will be done to determine the glutamate levels in the dACC (dorsal anterior cingulate cortex), basal ganglia and hippocampus and the glutamate/ creatine (Glu/Cr) ratio will be calculated.MRS utilizes a magnetic field to look at magnetic nuclei, which absorb and re-emit electromagnetic energy in the presence of the magnetic field. By looking at the peaks in the resultant spectra the structure and concentration of metabolites can be determin

Conditions Studied

Study Locations (1)

Georgia

  • Emory University Department of Psychiatry and Behavioral Sciences - Atlanta

Trial Details

FieldValue
Enrollment Target 98 participants
Start Date 2015-05
Est. Completion 2018-05-29
Emory University

1,208 total trials

What the finished NCT02421978 record still lists

NCT02421978 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT02421978 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT02421978 about?

NCT02421978 is a clinical study titled "Inflammation-Induced CNS Glutamate During Breast Cancer Treatment". The purpose of this study is to try and provide data linking the impact of increased inflammatory cytokines as a result of chemotherapy and their relationship with increased levels of CNS glutamate and related behavioral and cognitive consequences in breast cancer patients. The investigators will us...

What is the current status of trial NCT02421978?

This trial is currently completed. The enrollment target is 98 participants. The study started on 2015-05. Estimated completion is 2018-05-29.

What conditions does trial NCT02421978 study?

This clinical trial studies the following conditions: Breast Cancer.

Who is sponsoring clinical trial NCT02421978?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02421978 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02421978's enrollment target sits among peer trials

98 598th of 1224 higher than 622 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03382977 · 98 participants · Phase 1

    Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

  • NCT04577014 · 98 participants · Phase 1

    Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

  • NCT04817618 · 98 participants · Phase 3

    Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

  • NCT04860141 · 98 participants · Phase 4

    Efficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02421978, the US trial registry maintained by the National Library of Medicine. NCT02421978 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.